Published: 14 May 2024 393 views
Enter to win one of four grants to help advance your oncology research!
Supporting research discoveries needed for rapid development of personalized cancer treatments and therapies starts here.
We’re proud to recognize excellence in oncology research with tailored grant funding to support your continued discovery. As part of our Oncology Insights Grant Program, four researchers will be awarded an oncology-focused grant to use towards a service with GENEWIZ Multiomics & Synthesis Solutions from Azenta Life Sciences – including gene synthesis, precision antibody discovery using machine learning, next generation sequencing (NGS), and Olink® proteomics.
ENABLING IMPACTFUL BREAKTHROUGHS AND THERAPIES Brooks Life Sciences Services and Products business is rebranded under the creation of a new identity – Azenta Life Sciences. Azenta is dedicated to enabling life sciences organizations around the world to bring impactful breakthroughs and therapies to market – faster. Azenta Life Sciences encapsulates our commitment to helping customers reach new heights in their pursuit of scientific progress. By integrating our industry-leading capabilities, Azenta Life Sciences enterprise-wide sample exploration and management solutions will ... continue reading
Application Deadline | 24 May 2024 |
Value | $25,000 |
Country to study | United States |
Type | Fellowship |
Sponsor | Azenta Life Sciences |
Gender | Men and Women |
Oncology Grants
One $5,000 grant towards a Gene Synthesis oncology application
Traditional molecular cloning methods are often complex. Gene synthesis provides an efficient method to quickly generate constructs for exploration of cancer mechanisms in vitro, while also providing precise sequence vectors for therapeutic development. Leveraging gene synthesis in your oncology research can enable you to efficiently characterize the effects of genomic mutations on the mechanisms of cellular functions. Learn More >
One $10,000 grant towards a Precision Antibody Discovery oncology application
Selecting the right antibody leads from a large upstream pool with favorable downstream development characteristics the first time around is essential for successful, rapid therapeutic development. Combining NGS, machine learning bioinformatics, and recombinant antibody production into a singular workflow, our Precision Antibody Discovery service empowers you to rapidly discover diverse leads that you would otherwise miss with traditional screening technologies and processes– uncovering 5-10X more leads than low-throughput approaches. Learn More >
One $5,000 grant towards an NGS oncology application
Cancer researchers can use whole genome, exome, and targeted amplicon next generation sequencing (NGS) approaches to characterize cancer-associated mutations and other biomarkers. Leveraging the latest long-read and short-read technology, GENEWIZ Next Generation Sequencing can help you gain a wider perspective and understanding of your research with comprehensive genomic coverage. Learn More >
One $5,000 grant towards an Olink Proteomics® oncology application
Olink Proteomics enables high-throughput, simultaneous analysis of proteins with high specificity and sensitivity using minimal sample amounts to provide an in-depth understanding of disease and drug response. Using protein biomarker detection with Olink Proteomics, clinical trial researchers can identify known cancer biomarkers within a patient population to accurately identify subsets of the population with increased sensitivity to the therapeutic being tested. Learn More >
As part of our Oncology Insights Grant Program, four researchers will be awarded an oncology-focused grant to use towards a service with GENEWIZ Multiomics & Synthesis Solutions from Azenta Life Sciences – including gene synthesis, precision antibody discovery using machine learning, next generation sequencing (NGS), and Olink® proteomics.
The winners will be selected by our esteemed panel of judges and announced shortly after the conclusion of our multi-day, online Oncology Insights event.
Submit your abstract by May 24th, 2024 for consideration.
For more details visit: Azenta Life Sciences website.